SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
NEW YORK, Dec. 13, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On December 6, 2022, Gossamer issued a press release “announc[ing] topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).” Although the Company represented that seralutinib met the primary endpoint in the clinical trial, Wall Street analysts questioned its performance, noting that the therapy did not outperform Merck & Co. Inc’s sotatercept product.
On this news, Gossamer’s stock price fell $6.93 per share, or 74.6%, to close at $2.36 per share on December 6, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv
Robert S. Willoughby
888-476-6529 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-gossamer-bio-inc—goss-301701178.html
SOURCE Pomerantz LLP
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.